Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL), Hazardous Drug, Rx Only, Sterile, 5mL Multipl...
FDA Drug Recall #D-0651-2025 — Class II — September 5, 2025
Recall Summary
| Recall Number | D-0651-2025 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 5, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sandoz Inc |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 6 vials |
Product Description
Cyclophosphamide Injection 500 mg/5 mL (100 mg/mL), Hazardous Drug, Rx Only, Sterile, 5mL Multiple Dose Vial, Manufactured in Austria by Fareva Unterach GmbH for Sandoz Inc., Princeton, NJ 08540, Product of India, Vial NDC# 0781-3528-75, Carton NDC# 0781-3528-10.
Reason for Recall
cGMP deviations: Temperature excursion during transportation.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Only the following 6 GTN Numbers for Lot # 110459 exp. date 02/28/2027: (01)00307813528104(21)10686040629319 (01)00307813528104(21)10687281435306 (01)00307813528104(21)10687409963168 (01)00307813528104(21)10701200331212 (01)00307813528104(21)10687325644911 (01)00307813528104(21)10687661160169
Other Recalls from Sandoz Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0626-2025 | Class II | Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic ... | Aug 13, 2025 |
| D-0569-2025 | Class I | Cefazolin for Injection, USP, 1 gram per vial, ... | Jun 27, 2025 |
| D-0570-2025 | Class I | Buffered Penicillin G Potassium for Injection, ... | Jun 27, 2025 |
| D-0286-2022 | Class I | Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL,... | Nov 17, 2021 |
| D-0162-2020 | Class III | Neomycin and Polymyxin B Sulfates and Dexametha... | Oct 17, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.